Let's see those badges
Executive Summary
Merck will re-emphasize its training for sales representatives at medical meetings regarding unsolicited requests for off-label information. According to a letter from the ad division to Merck July 19, a Merck sales rep asked a visitor to the company's booth at the American Society of Clinical Oncology meeting, "would you like to have off-label information sent to you about Cancidas?" and ran the visitor's name tag through a bar code reader. The company then mailed information about unapproved uses for the antifungal agent (capsofungin) under a cover letter stating that "this is in response to your request." Merck said it uses the bar code reader to expedite genuine requests for information, and the behavior described by FDA violates its policy. FDA describes similar behavior by a Schering-Plough Temodar (temozolomide) sales rep at the ASCO meeting in a June 28 letter to the company
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth